Radiopharm Theranostics (Radiopharm Theranostics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Radiopharm Theranostics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Radiopharm Theranostics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Radiopharm Theranostics's Cash-to-Debt or its related term are showing as below:

RDPTF' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 2 years, Radiopharm Theranostics's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

RDPTF's Cash-to-Debt is ranked better than
99.8% of 1478 companies
in the Biotechnology industry
Industry Median: 7.005 vs RDPTF: No Debt

Radiopharm Theranostics Cash-to-Debt Historical Data

The historical data trend for Radiopharm Theranostics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Radiopharm Theranostics Cash-to-Debt Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Cash-to-Debt

No Debt

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Radiopharm Theranostics's Cash-to-Debt

For the Biotechnology subindustry, Radiopharm Theranostics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Cash-to-Debt falls into.

Radiopharm Theranostics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Radiopharm Theranostics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Radiopharm Theranostics had no debt ⁽¹⁾.

Radiopharm Theranostics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Radiopharm Theranostics had no debt ⁽¹⁾.

Radiopharm Theranostics (OTCPK:RDPTF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Radiopharm Theranostics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.